Optimized formulation buffer preserves adeno-associated virus-9 infectivity after 4 °C storage and freeze/thawing cycling
Authors:
Open Access
- 5 August 2022
- journal article
- research article
- Published by Elsevier in Journal of Virological Methods
- Vol. 309, 114598
Abstract
No abstract availableKeywords
Funding Information
- NIH Blueprint for Neuroscience Research (P40OD010996)
This publication has 34 references indexed in Scilit:
- The Assembly-Activating Protein Promotes Capsid Assembly of Different Adeno-Associated Virus SerotypesJournal of Virology, 2011
- Reversal of Blindness in Animal Models of Leber Congenital Amaurosis Using Optimized AAV2-mediated Gene TransferMolecular Therapy, 2008
- Freeze-thaw increases adeno-associated virus transduction of cellsAmerican Journal of Physiology-Cell Physiology, 2006
- Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulationMolecular Therapy, 2005
- Large-scale production, purification and crystallization of wild-type adeno-associated virus-2Journal of Virological Methods, 2004
- Development of stable liquid formulations for adenovirus-based vaccinesJournal of Pharmaceutical Sciences, 2004
- Development of formulations that enhance physical stability of viral vectors for gene therapyGene Therapy, 2001
- Recombinant adeno-associated virus purification using novel methods improves infectious titer and yieldGene Therapy, 1999
- Factors that Influence Stability of Recombinant Adenoviral Preparations for Human Gene TherapyPharmaceutical Development and Technology, 1998
- EFFECTS OF THE INTRAVENOUS ADMINISTRATION OF GLYCEROL SOLUTIONS TO ANIMALS AND MAN1Journal of Clinical Investigation, 1958